Investment Banking
Joint Bookrunner on Lexeo Therapeutics’ $143.8 Million CMPO
October 27, 2025
Lexeo Therapeutics, Inc. (Nasdaq: LXEO) (“Lexeo”), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced the closing of an underwritten public offering and concurrent private placement, for total gross proceeds to Lexeo of approximately $153.8 million, including the full exercise of the underwriters’ option to purchase additional shares.
In the public offering, Lexeo sold 17,968,750 shares of its common stock at $8.00 per share, which includes the full exercise of the underwriters’ option to purchase 2,343,750 shares of Lexeo’s common stock. The gross proceeds to Lexeo from the public offering were approximately $143.8 million.
Concurrent with the public offering, Lexeo sold pre-funded warrants to purchase 1,250,015 shares of its common stock to Balyasny Asset Management at a price of $7.9999 per pre-funded warrant, in a private placement. The gross proceeds to Lexeo from the private placement were approximately $10 million.
The net proceeds received from the offering are intended to be used to advance the clinical development of LX2006, including funding of the registrational study and the CMC and commercial readiness activities, to fund the ongoing clinical development of LX2020, including completion of the ongoing Phase 1/2 study, to fund the continued development of other programs and cardiac discovery efforts, and for other research and development opportunities, working capital and other general corporate purposes.
Senior Managing Director, Head of Healthcare Investment Banking
Managing Director, Healthcare Capital Markets Investment Banking
Managing Director, Healthcare Capital Markets Investment Banking
This notice is provided for informational purposes only and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.
This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.
Oppenheimer & Co. Inc. Transacts Business on all Principal US Exchanges and is a Member of SIPC. 8527911.1
